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 The 21st century has brought with it a welcome call for increased rigor in observational research 
methods (1, 2). It is not that observational research methods are inherently flawed – they are 
not (3, 4). Observational studies can contribute valuable evidence supporting causal 
associations when designed and conducted using rigorous methods. The “flaws” are a result of 
reliance on outdated methodology, inadequate attention to threats to validity (such as 
confounding), opaque reporting of results, lack of replication, and a failure to interpret findings 
within the context of the limitations of observational research methodology.  
Aware of this situation and influenced by our experience as journal editors, we 
convened an ad hoc group of 47 editors of 35 respiratory, sleep, and critical care journals to 
offer guidance to authors, peer reviewers, and researchers on the design and reporting of 
observational causal inference studies. This guidance takes the form of a call for investigators to 
consider making major changes to their approach to such studies. This document represents 
our current best understanding of approaches to causal inference, an active area of research. 
We anticipate that best practice in this, as in any scientific endeavor, will continue to evolve, 
requiring this document to be updated every 5 to 10 years. We believe these changes will 
increase the rigor, validity, and value of the work we publish in our journals.  
What Is Causal Inference? 
We first wish to make a distinction between causal inference and prediction modeling. Causal 
inference is the examination of causal associations to estimate the causal effect of an exposure 
on an outcome. We use causal inference to answer questions about etiology: Does long-term 
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 exposure to traffic-related air pollution promote obstructive sleep apnea in non-obese adults? 
Does caffeine intake protect against pulmonary arterial hypertension? Do anti-depressants 
reduce the risk of the ARDS in adults with community-acquired pneumonia? Both experimental 
studies (e.g., randomized clinical trials) and observational studies (e.g., cohort, case-control, 
and cross-sectional studies) can be used to examine causal associations. We encourage authors 
to design observational studies that emulate the clinical trial they would have designed to 
answer the causal question of interest (5, 6). Causal inference studies require a clearly 
articulated hypothesis, careful attention to minimizing selection and information bias, and a 
deliberate and rigorous plan to control confounding. The latter is addressed in detail later in 
this document.  
Prediction models are fundamentally different than those used for causal inference (7). 
Prediction models use individual-level data (predictors) to estimate (predict) the value of an 
outcome. For example, one might wish to predict an adult’s 10-year risk of developing lung 
cancer. Investigators might use machine learning methods, penalized estimation, or one of 
many other available methods to develop a prediction model using a dataset containing both 
the predictors of interest and lung cancer event data. A risk score calculator (or other clinically 
useful tool) could then be developed, validated, disseminated, and implemented in practice. 
This document does not address development, validation, or reporting of prediction model. 
With this background, we offer three key principles to guide authors in the analysis and 
reporting of causal inference studies (Table 1): 
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Key Principle #1: Causal Inference Requires Careful Consideration of 
Confounding  
Herein, we focus on how one should define and select confounders in observational studies 
that attempt to make causal inferences. Based on our experience, we have identified 5 
approaches commonly used by authors (Table 1). Only two of these methods (the “historical” 
approach and causal modeling), however, aid in causal inference. The others, those based on 
statistical hypothesis testing or model fit, do not. We detail each approach below: 
Historical Approach to Defining a Confounder 
A confounder has long been defined as any third variable that is associated with the exposure 
of interest, is a cause of the outcome of interest, and does not reside in the causal pathway 
between the exposure and outcome (Figure 1A) (8). We find this definition reasonable, and we 
regard it as an acceptable approach to address confounding in studies of causal inference. 
Importantly, as clarified later, we expect authors to purposefully select variables that plausibly 
fit these criteria based on prior knowledge rather than selecting those variables associated with 
the exposure or outcome using the available data. 
Using Causal Models to Identify Confounding 
While the historical approach described above is acceptable for simple causal structures, it is 
often inadequate to describe the more commonly encountered causal networks. Hence, we 
urge authors to consider using causal models when testing causal associations.  
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The scientific, mathematical, and theoretical underpinnings of causal inference, 
developed by Judea Pearl, James Robins, Miguel Hernán, and others, have evolved sufficiently 
to permit the everyday use of causal models (9-17). Causal models can be represented visually 
using directed acyclic graphs (DAGs). A DAG is a graph in which unidirectional arrows are used 
to represent known causal effects (based on prior knowledge). While investigators often feel 
some discomfort in deciding what causal effects do and do not exist based on prior knowledge, 
the advantage of this approach is that it makes these assumptions explicit (and hence 
transparent). In fact, all other methods of controlling for confounding involve implicit 
assumptions about causal effects, which are not transparent to the reader.  
Four simple DAGs are shown in Figure 1. Within a DAG, a “path” is a set of arrows 
connecting any two variables (regardless of arrow direction). The causal path of interest is the 
hypothesized association between the exposure and outcome. A “back-door path” is an 
alternate path between the exposure and the outcome. Confounding is defined as the presence 
of at least one “open” back-door path between exposure and outcome. Variables that naturally 
open back-door paths are called confounders. An association will exist between any two 
variables connected by an open path. When an investigator “controls” for a confounder, the 
back-door path will be “closed,” and the association between the exposure and outcome will no 
longer be observed. 
As an example, suppose an investigator is testing whether exercise is associated with a 
reduced risk of lung cancer. In Figure 1A, there is one causal path: exercise  lung cancer, and 
one back-door path: exercise  smoking  lung cancer. This open back-door path indicates 
the presence of confounding, and therefore smoking is a confounder of the causal association 
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between exercise and lung cancer. Note that we define a confounder here as a variable that, 
when controlled for, closes a back-door path. 
When more than one variable lies along a back-door path, control of a single 
confounder on the path is sufficient to close the back-door path. In a fully developed DAG with 
many paths, control of a small number of variables (a “minimum set” of confounders) will often 
close all back-door paths. We recommend using this approach in causal inference studies. 
DAGitty.net offers authors a simple interface with which to construct DAGs and identify back-
door paths and minimum sets of confounders (18).  
Figure 1B adds another type of variable -- a mediator -- to the DAG. A mediator is a 
variable that lies along the causal path (not a back-door path) between the exposure and 
disease. Mediators are, of course, of great interest, since they are causes and mechanisms of 
disease. In Figure 1B, the mediator is “immune function.” At least some of the causal effect of 
exercise on lung cancer risk is mediated by exercise-induced changes: exercise  immune 
function  lung cancer. A path that includes a mediator is often called an indirect effect or 
indirect causal path. In contrast, the arrow directly connecting exercise and lung cancer 
represents the direct causal effect of exercise on lung cancer not due to changes in immune 
function.   
Mediators naturally leave the indirect causal path open. Control of a mediator (through 
adjustment or other means) will close the indirect causal path, preventing or limiting the ability 
to observe an association between the exposure and outcome (if indeed one exists). Mediators 
therefore require special attention (if they are to be examined at all) and should not be treated 
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as confounders. Use of a DAG can aid investigators in identifying mediators, thereby avoiding 
control of these variables in testing causal effects.  
A discussion of “collider bias” further illustrates the value of using DAGs. A “collider” is a 
variable with two or more antecedent causes that lie within a pathway of interest. A collider 
can be identified on a DAG when two arrows along a path both point to a variable (Figure 1C). 
When both the exposure and outcome are causes of the collider, one may be tempted to 
control for the collider. However, colliders naturally block back-door paths. Controlling for a 
collider will open the back-door path, thereby introducing confounding.  
For example, in Figure 1C we are interested in testing the causal association between 
shift work and obstructive sleep apnea. We might be tempted to control for sleepiness, since 
both shift work and obstructive sleep apnea cause sleepiness. However, sleepiness is a collider 
that naturally blocks the back-door path of shift work  sleepiness  obstructive sleep apnea. 
Controlling for sleepiness would open this back-door path, introducing confounding.  
To clarify, imagine that, in reality, shift work is not a cause of obstructive sleep apnea. If 
we encountered a sleepy person with obstructive sleep apnea, their sleep apnea would likely 
be the cause of their sleepiness, and therefore they would be less likely to be a shift worker. 
Conversely, if we encountered a sleepy shift worker, it is likely that shift work is the cause of 
their sleepiness rather than obstructive sleep apnea. We would therefore observe that sleep 
apnea occurs less commonly among shift workers, and thus report an inverse association. This 
confounded association results from conditioning on a collider (in this case, by only examining 
sleepy people). The same bias would occur if we were to adjust for sleepiness using a 
regression model. 
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Collider bias may also be present when neither the exposure nor the outcome is a direct 
cause of the collider variable. An example is “M-bias,” named after the shape of the DAG 
(Figure 1D) (19). In this example, we are testing the causal association between chronic beta-
blocker use and the risk of developing ARDS. We might be tempted to adjust for the presence of 
auscultatory crackles at hospital admission, since: (a) heart failure leads to both chronic beta-
blocker therapy and crackles; and (b) pneumonia causes both ARDS and crackles. These 
relationships may lead us to believe that “crackles” is a confounder, whereas in reality it is not. 
Instead, as Figure 1D shows, “crackles” is a collider on the back-door path of chronic beta-
blocker therapy  heart failure  crackles  pneumonia  ARDS. Adjusting for the presence 
of crackles opens this back-door path, introducing confounding. Ignoring the presence of 
crackles would be the right thing to do.  
We encourage investigators that wish to control for variables that do not close a back-
door path to ensure that these additional variables are neither mediators nor colliders. 
DAGs do come with limitations. They are non-parametric by nature. The directionalities 
of effects are not always known. DAGs are prone to misspecification when there is a lack of 
strong background information, and constructing a DAG can be challenging, with even small 
errors potentially leading to incorrect inferences. Despite these limitations, DAGs lay bare the 
assumptions made by the investigators, which can then be identified and corrected more 
readily during pre- and post-publication peer review than through more opaque methods. 
This brief document cannot provide a detailed discussion of causal inference, but we 
hope that these examples encourage authors to consider using causal models in their research. 
We refer authors to a number of excellent resources on the topic (Table 2).  
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Variable Selection Methods That Do Not Adequately Control for Confounding 
P-value-based and model-based variable selection methods (including forward, backward, and 
stepwise selection) should not be used for causal inference. These approaches ignore the causal 
structure underlying the hypothesis and therefore do not adequately control for confounding. 
Confounders and colliders are treated similarly. Methods relying on model fit or related 
constructs (such as r2, Akaike information criterion, and Bayesian information criterion) also 
have no relevance to causal inference. These methods rely heavily on the available data, in 
which causal relationships may or may not have been captured and may or may not be evident. 
Specification of the model and the arbitrary variables included in any particular model will drive 
observed associations with the outcome.  
Selection of variables that, when included in a model, change the magnitude of the 
effect estimate of the exposure of interest should not be used to identify confounders, for the 
reasons discussed above.  
Identification of multiple “independent predictors” (“winners”) through purposeful or 
automated variable selection is an unacceptable approach for testing causal associations. If the 
authors have hypotheses about each variable, then a separate model for each variable should 
be generated using one of the above preferred approaches. Alternatively, a prediction model 
could be developed, if prediction, rather than causal inference, is the goal of the analysis. 
“Table 2 Fallacy” 
Causal models are typically designed to test an association between a single exposure and an 
outcome. The additional independent variables in a model (often called “covariates”) serve to 
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control for confounding. The observed associations between these covariates and the outcome 
have not been subject to the same approach to control of confounding as the exposure. 
Therefore, residual confounding and other biases often heavily influence these associations. 
This situation is known as “Table 2 Fallacy,” a term arising from the practice of presenting effect 
estimates for all independent variables in “Table 2” (20). We strongly caution authors to avoid 
presenting these effect estimates in the primary manuscript. 
Causal Association, Causal Effect, and Claiming Causality 
Readers may find it unusual that we are using the word “causal” to describe observed 
associations. When examining associations in observational causal inference studies, the 
intention is always to seek evidence to support (or refute) a true causal effect of the exposure 
on the outcome. Of course, we often cannot establish these causal effects from any single 
study. Yet, by acknowledging the intent, it is reasonable to use the label “causal association” 
(but not “causal effect”) to describe findings arising from an observational study.  
We therefore caution authors that claims of causality should be avoided without 
substantial evidence of a true causal effect, as espoused by Bradford Hill and further developed 
by John Ioannidis (21, 22). It is reasonable to use the term “effect estimate” when referring to a 
causal association in an observational study, but assertions that an exposure has an “effect” or 
“impact” on the outcome, or that the exposure “protects against” or “promotes” the outcome 
should not be made. 
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 A Note on Methods to Control for Confounding 
Investigators may control for confounding either in the design or analysis of a study. 
Randomization to exposure, use of an instrumental variable, weighted regression via 
propensity-scores, adjustment using multivariable regression, stratification on a confounder, 
conditioning enrollment on a confounder (restriction), and matching on a confounder are 
common methods (4). We do not make recommendations for or against any of these methods. 
Key Principle #2: Interpretation of Results Should Not Rely on the Magnitude of 
P-Values
In recent years, the merits of the p-value in causal inference have been questioned (23-26). P-
values are frequently misinterpreted and misused (27). Although some disagree (28), they 
provide no information about the magnitude, direction, or clinical importance of an association. 
Accordingly, we recommend that P-values only rarely be presented in isolation (exceptions may 
include “omics” studies and tests for interaction). Effect estimates and measures of precision 
(e.g., confidence intervals or credible intervals) should be presented in addition to (or in place 
of) p-values.  
We recommend interpreting the variability around an effect estimate when making 
conclusions about causal associations. For example, a rate ratio of 2.1 with a confidence 
interval of 0.97 to 4.2 and a corresponding p-value of 0.10 should not be reported as “no 
association,” since a rate ratio as large as 4.2 has not been plausibly excluded, and, at least 
within the study sample, an association was indeed observed. Instead, a statement such as 
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“The exposure was associated with a 2.1-fold increased rate of the outcome (95% confidence 
interval 0.97 to 4.2), but this estimate is imprecise” would be sufficient. In this example, the 
point- and interval-estimates are informative, yet (not surprisingly) the hypothesis test was 
inconclusive. Similarly, we recommend against using the vague labels “significant” and “non-
significant,” which lead readers (and authors) to implicitly conclude that an association is 
present or absent. Use of the unqualified word “significant” tends to blur the important 
distinction between statistical significance and clinical significance. We favor simply reporting 
the quantitative findings as indicated above. The clinical, mechanistic, or biological 
interpretations of effect sizes provide greater value and should be used in place of these labels. 
Key Principle #3: Results Should Be Presented in a Granular and Transparent 
Fashion 
The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement, 
published in 2007, provides clear and valuable guidance on the reporting of results of human 
observational studies that test causal associations (29). We strongly recommend that authors 
adhere to the STROBE statement when reporting results, including the detailed guidance 
provided in the STROBE “Explanation and Elaboration” Document (30). In particular, when 
applicable, results should be presented in Tables modeled after those in Sections 15 and 16 of 
the STROBE “Explanation and Elaboration” Document (30), with the following in mind: 
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• In cohort studies, tabular presentation of results should include the number of events,
person-time, incidence rates, and unadjusted and adjusted incidence rate ratios for each
exposure level.
• In cross-sectional studies, tabular presentation of results should include the number of
events, prevalences, and unadjusted and adjusted prevalence ratios for each exposure
level.
• In case-control studies, tabular presentation of results should include the number and
percent exposed for cases and controls separately, and unadjusted and adjusted odds
ratios for each case group.
We encourage authors to take a thoughtful and careful approach to the visual
presentation of quantitative results (31). When possible, presentation of individual data points 
should accompany measures of central tendency and variation. The “data-ink ratio” should be 
maximized by avoiding unnecessary lines, grids, and text (31). Abbreviations should be used 
sparingly. Continuous data should not be presented in bar charts with standard error bars 
(“plunger plots”) (32, 33). Authors should use color-blind friendly palettes. 
Final Comment to Our Authors 
This document is intended to provide firm guidance rather than absolute rules; to raise the 
rigor of the work reported in our journals; to improve the communication of research findings; 
to enhance the value and validity of the science in our field; to aid in replication; and, most 
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importantly, to improve the health of those living with respiratory disease, sleep disorders, and 
critical illness.  
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 Figure Legends 
Figure 1: Directed acyclic graphs illustrating (A) confounding, (B) mediation, (C) collider bias, 
and (D) M-bias. Each arrow represents a causal effect. In (A), the blue arrows represent an open 
back-door path: exercise  smoking  lung cancer. “Smoking” is a confounder that naturally 
leaves the back-door path open. Controlling for “smoking” will close the back-door path, 
eliminating confounding through this path. In (B), the black arrows all represent the direct and 
indirect causal paths of interest. “Immune function” partially mediates the association between 
exercise and lung cancer: exercise  immune function  lung cancer. Control of “immune 
function” would be inappropriate, since it would partially close the causal path, attenuating the 
observed association between exercise and lung cancer. In (C), the orange arrows represent a 
closed back-door path: shift work  sleepiness  obstructive sleep apnea. “Sleepiness” is a 
collider that naturally leaves the back-door path closed. Control of “sleepiness” would open the 
back-door path, introducing confounding through this path. In (D), the orange arrows represent 
a closed back-door path: chronic beta-blocker therapy  heart failure  crackles  
pneumonia  acute respiratory distress syndrome. “Crackles” is a collider that naturally leaves 
the back-door path closed. Control of “crackles” would open the back-door path, introducing 
confounding through this path.  
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 Table 1: Key Principles 
Key Principle #1: Causal inference requires careful consideration of confounding 
• Preferred variable selection methods
1. Historical confounder definition with purposeful variable selection
2. Causal models using directed acyclic graphs
• Variable selection methods that do not adequately control for confounding
3. P-value or model-based methods
4. Methods based on beta-coefficient changes
5. Selection of variables to identify “independent predictors”
• Do not present all of the effect estimates from a model designed to test a single causal
association (“Table 2 fallacy”).
Key Principle #2: Interpretation of results should not rely on the magnitude of p-values 
• P-values should rarely be presented in isolation.
• Present effect estimates and measures of variability with or without p-values.
• Variability around effect estimates should inform conclusions.
• A conclusion of “no association” should require exclusion of meaningful effect sizes.
• Avoid the word “significant” in favor of more specific language.
Key Principle #3: Results should be presented in a granular and transparent fashion. 
• Use the STROBE statement and checklist.
• Model tables after the STROBE “Explanation and Elaboration” Document (Reference #31).
• Visual presentation of quantitative results
o Present individual data points when possible.
o Avoid excessive lines, text, grids, and abbreviations.
o Continuous data should not be presented in bar charts with standard error bars
(“plunger plots”).
o Use color-blind friendly palettes
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Table 2: Causal Inference Resources 
Books 
• Pearl, J. (2018). The Book of Why: The New Science of Cause and Effect. Basic Books;
1st edition.
• Pearl J. (2009). Causality: Models, Reasoning and Inference. Cambridge University
Press; 2nd edition.
• Hernán MA, Robins JM (2018). Causal Inference. Boca Raton: Chapman & Hall/CRC,
forthcoming. (Available at: https://www.hsph.harvard.edu/miguel-hernan/causal-
inference-book/)
Articles 
• Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research.
Epidemiology 1999;10(1):37-48.
• Greenland S. Quantifying biases in causal models: classical confounding vs collider-
stratification bias. Epidemiology. 2003;14(3):300-6.
• Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias.
Epidemiology 2004;15(5):615-25.
• Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment
in epidemiologic studies. Epidemiology. 2009;20(4):488-95.
• Morabia A. History of the modern epidemiological concept of confounding. J Epidemiol
Community Health. 2011;65(4):297-300.
• Williamson EJ, Aitken Z, Lawrie J, Dharmage SC, Burgess JA, Forbes AB. Introduction to
causal diagrams for confounder selection. Respirology 2014;19(3):303-11.
• Hernán MA. The C-Word: Scientific euphemisms do not improve causal inference from
observational data. Am J Public Health. 2018;108(5):616-619.
Websites 
• An online course about causal inference and directed acyclic graphs:
https://www.edx.org/course/causal-diagrams-draw-assumptions-harvardx-ph559x.
Causal Diagrams: Draw Your Assumptions Before Your Conclusions. By Miguel Hernán.
• A web-based environment for creating directed acyclic graphs: http://dagitty.net.
Textor J, van der Zander B, Gilthorpe MK, Liskiewicz M, Ellison GTH. Robust causal
inference using directed acyclic graphs: the R package 'dagitty'. International Journal of
Epidemiology 45(6):1887-1894, 2016.
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